8F2D

SARS-CoV-2 Main Protease (Mpro) in Complex with ML4006a

8F2D の概要

• エントリーDOI: 10.2210/pdb8f2d/pdb
• 関連するPDBエントリー: 7SET 7SF1 7SF3 7SFB 7SFH 7SFI 7SGH 7U92 7UUG 7UUP 8EZV 8EZZ 8F02 8F2C
• 分子名称: 3C-like proteinase nsp5, (1R,2S,5S)-N-[(2S,3R)-4-(azetidin-1-yl)-3-hydroxy-4-oxo-1-(2-oxopiperidin-1-yl)butan-2-yl]-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, CHLORIDE ION, ... (4 entities in total)
• 機能のキーワード: sarscov2, sars-cov-2, coronavirus, main protease, protease, mpro, 3c-like proteinase, cl3pro, inhibitor, complex, covalent, adduct, m4006a, ketoamide, azetidine, peptidomimetic, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 34462.66

構造登録者

Westberg, M.,Fernandez, D.,Lin, M.Z. (登録日: 2022-11-07, 公開日: 2023-10-11, 最終更新日: 2024-03-20)

• 主引用文献: Westberg, M.,Su, Y.,Zou, X.,Huang, P.,Rustagi, A.,Garhyan, J.,Patel, P.B.,Fernandez, D.,Wu, Y.,Hao, C.,Lo, C.W.,Karim, M.,Ning, L.,Beck, A.,Saenkham-Huntsinger, P.,Tat, V.,Drelich, A.,Peng, B.H.,Einav, S.,Tseng, C.K.,Blish, C.,Lin, M.Z.; An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.; Sci Transl Med, 16:eadi0979-eadi0979, 2024; PubMed: 38478629; DOI: 10.1126/scitranslmed.adi0979

実験手法

X-RAY DIFFRACTION (1.95 Å)